Free Trial
→ The investigation Porter spent tens of thousands to document (From Porter & Company) (Ad)tc pixel
NASDAQ:RLAY

Relay Therapeutics Q3 2026 Earnings Date & Estimates

Relay Therapeutics logo
$18.35 -1.12 (-5.75%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$18.34 -0.02 (-0.08%)
As of 10/30/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Relay Therapeutics is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. The conference call is scheduled for 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Relay Therapeutics in Q3 2026

Relay Therapeutics is expected to post earnings of -$0.3964 per share on revenue of $1.62 million. In the same quarter a year earlier Relay Therapeutics reported -$0.43 per share. Relay Therapeutics last reported on August 6, 2026, posting -$0.41 per share and missing the -$0.3911 consensus estimate. Relay Therapeutics has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.3964
Expected Revenue
$1.62 million
Prior-Year EPS
-$0.43

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.41 (Missed by -$0.0189)
Last Quarter Revenue
$350 thousand
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Relay Therapeutics Q3 2026 Earnings FAQ

Relay Therapeutics (NASDAQ:RLAY) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Relay Therapeutics' Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Relay Therapeutics to post earnings of -$0.3964 per share for Q3 2026.

The consensus revenue estimate for Relay Therapeutics is $1.62 million for Q3 2026.

Relay Therapeutics Earnings Headlines

Analyzing Praxis Precision Medicines (NASDAQ:PRAX) and Relay Therapeutics (NASDAQ:RLAY)
October 29 at 3:58 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31165903
Relay Therapeutics to Report Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026
October 28 at 4:30 PM  |  quiverquant.comQ
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
 |  Porter & Company (Ad)
Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026
October 28 at 4:12 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/28/3390754/0/en/relay-therapeutics-to-announce-third-quarter-2026-financial-results-and-corporate-highlights-on-november-4-2026.html
Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock Has Consensus Target Price of $25.92
October 23, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31148401
Relay: The Recent Market Excitement Ignores The Reality Of Clinical Risks And Patent Cliffs
October 17, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4954846-relay-the-recent-market-excitement-ignores-the-reality-of-clinical-risks-and-patent-cliffs
See More Relay Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Relay Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Relay Therapeutics and other key companies, straight to your email.

About Relay Therapeutics

Relay Therapeutics (NASDAQ:RLAY) is a biotechnology company focused on discovering and developing medicines for cancer and other serious diseases. The company uses its Dynamo platform, which combines structural biology, computational modeling, machine learning and experimental science to study how proteins move and interact. Relay aims to use this approach to identify precisely targeted therapies, including medicines designed to bind to previously difficult-to-drug sites.

The company’s pipeline has primarily focused on oncology, including investigational small-molecule therapies directed at cancer-driving proteins and signaling pathways. Its programs have included treatments targeting PI3K alpha, FGFR2 and other molecular targets, although candidates and development priorities may change as clinical research progresses. Relay’s products remain investigational and are subject to clinical testing and regulatory review.

Relay Therapeutics was founded in 2016 and is headquartered in Cambridge, Massachusetts. The company has advanced its programs through internal research as well as collaborations and partnerships with other biopharmaceutical organizations. Sanjiv Patel serves as the company’s president and chief executive officer.

View Relay Therapeutics Profile
Earnings Tools